Haeberlein SB, Gheuens S, Chen T, et al. Aducanumab 36-month data from PRIME: a randomized, double-blind, placebocontrolled phase 1b study in patients with prodromal or mild Alzheimer’s disease. AAN 2018, S2.004.
Podcast voor coassistenten: basaal en praktisch
nov 2023 | Bewegingsstoornissen, Dementie, Epilepsie, Multipele Sclerose, Neuro-musculair, Neuro-oncologie, Neuro-vasculair